“It was a pleasure for us in Sopharma to accept being a host from “Games for Good” for the...
Sopharma Towers turned into a really magical place where the greatest power was children’s...
Jump to navigation
Sopharma AD works to ensure health equity and access to quality and effective treatment for patients in all its markets through affordable high quality medicines and widening its generic portfolio.
The company transferred its medicine donations policy to a different stage in order to ensure the right treatment for every different case in collaboration with our partner BCAF and other partners.
The positions of the main competitors of the company in Bulgaria are as follows:
Bulgarian market share
In units (%)
|Share of the total Bulgarian market in units as at 31.03.2022%|
|Novartis||3.81% in units|
|Roche||0.16% in units|
|Merck||0.14% in units|
|Teva||8.53% in units|
|Pfizer||0.75% in units|
|Abbvie||0.06% in units|
|AstraZeneca||0.49% in units|
|Swixx Bipharma||0.98% in units|
|Sopharma||10.08% in units|
In values (%)
|Share of the total Bulgarian market in value as at 31.03.2022 %|